

The evidence base most supplements wish they had. 2 g daily of EPA+DHA moves triglycerides, shifts inflammation, and shows up on the cardiovascular endpoints that actually matter.
EPA and DHA shift membrane fatty-acid composition and downregulate pro-inflammatory eicosanoids. At 2 g/day, trials show 20-30% triglyceride reduction in elevated baseline; REDUCE-IT showed a 25% relative risk reduction in cardiovascular events at higher EPA doses in high-risk subjects. The Omega-3 index (RBC EPA+DHA) is the right marker - serum is noise.
Take two softgels with food. Daily use supports steady blood levels.
Subscribe & Save
Cancel anytime
$30/mo
One-time
Trial run
$34
Related reading
Longevity
ApoB, hs-CRP, HbA1c, fasting insulin, thyroid. Re-measured every quarter. Sequenced by a provider. Never sold as a stack.
ReadMetformin for longevity: what we know and what remains uncertain
Metformin is often framed as a longevity shortcut, but evidence strength differs by population and endpoint. It has a clear role in glycemic management and...
ReadNAD and longevity markers: what we know, what's hype
NAD+ IV drips sell at $400-800 a session. NMN bottles have become the supplement aisle's hottest trend. Meanwhile, the labs with the strongest longevity...
ReadOmega-3 index
RBC EPA+DHA percentage. The only magnesium-style marker that reflects long-term fatty acid status.
ReadLongevity foundational biomarker stack
Quarterly biomarker loops before advanced supplements or peptide layering.
ReadMen's Health
Low T is rarely the whole answer. Thyroid, sleep, iron, lipids, and training load shape the outcome before testosterone does.
Read